A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC50 values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [(18)F]4, [(18)F]5, and [(18)F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [(18)F]5 and [(18)F]6 as favorable candidates for future prostate cancer imaging clinical trials.
A series of phosphoramidate-based n class="Gene">prostate specific membrane antigen (PSMA) inhibitors of increasing lipophilicity were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron emission tomography (PET) imaging agents for prostate cancer. To gain insight into their modes of binding, they were also cocrystallized with the extracellular domain of PSMA. All analogs exhibited irreversible binding to PSMA with IC50 values ranging from 0.4 to 1.3 nM. In vitro assays showed binding and rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells. In vivo distribution demonstrated significant uptake in CWR22Rv1 (PSMA(+)) tumor, with tumor to blood ratios of 25.6:1, 63.6:1, and 69.6:1 for [(18)F]4, [(18)F]5, and [(18)F]6, respectively, at 2 h postinjection. Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [(18)F]5 and [(18)F]6 as favorable candidates for future prostate cancer imaging clinical trials.
Authors: Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531
Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Valerie Humblet; Rena Lapidus; Larry R Williams; Takashi Tsukamoto; Camilo Rojas; Pavel Majer; Bunda Hin; Shunsuke Ohnishi; Alec M De Grand; Atif Zaheer; Jürgen T Renze; Akira Nakayama; Barbara S Slusher; John V Frangioni Journal: Mol Imaging Date: 2005 Oct-Dec Impact factor: 4.488
Authors: Cyril Barinka; Miroslava Rovenská; Petra Mlcochová; Klára Hlouchová; Anna Plechanovová; Pavel Majer; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski Journal: J Med Chem Date: 2007-06-14 Impact factor: 7.446
Authors: Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper Journal: J Med Chem Date: 2008-07-19 Impact factor: 7.446
Authors: Jessie R Nedrow; Joseph D Latoche; Kathryn E Day; Jalpa Modi; Tanushree Ganguly; Dexing Zeng; Brenda F Kurland; Clifford E Berkman; Carolyn J Anderson Journal: Mol Imaging Biol Date: 2016-06 Impact factor: 3.488
Authors: Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson Journal: Acta Crystallogr D Biol Crystallogr Date: 2009-12-21
Authors: Søren Brøgger Christensen; Henrik Toft Simonsen; Nikolai Engedal; Poul Nissen; Jesper Vuust Møller; Samuel R Denmeade; John T Isaacs Journal: Prog Chem Org Nat Prod Date: 2021
Authors: Falguni Basuli; Tim E Phelps; Xiang Zhang; Carolyn C Woodroofe; Jyoti Roy; Peter L Choyke; Rolf E Swenson; Elaine M Jagoda Journal: Pharmaceuticals (Basel) Date: 2022-05-13
Authors: Sinan Wang; Jun Li; Jun Hua; Yang Su; Denis R Beckford-Vera; Walter Zhao; Mayuri Jayaraman; Tony L Huynh; Ning Zhao; Yung-Hua Wang; Yangjie Huang; Fujun Qin; Sui Shen; Daniel Gioeli; Robert Dreicer; Renuka Sriram; Emily A Egusa; Jonathan Chou; Felix Y Feng; Rahul Aggarwal; Michael J Evans; Youngho Seo; Bin Liu; Robert R Flavell; Jiang He Journal: Clin Cancer Res Date: 2020-12-08 Impact factor: 13.801